FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Temporal Profile of Treatment-Emergent Adverse Events in Adult Asian Patients with Focal-Onset Seizures During Adjunctive Brivaracetam Treatment: Post Hoc Analysis of a Phase 3, Randomized Trial. PMID 40944847 · Adv Ther · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Design of RESOLVE Lung, a multinational Phase 2, randomized, placebo-controlled trial of the anti-GM-CSF monoclonal antibody namilumab in patients with chronic pulmonary sarcoidosis. PMID 40939735 · Contemp Clin Trials · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Eligibility criteria in phase 3 randomized controlled trials in gastric cancer. PMID 40932583 · Gastric Cancer · 2025-Nov The publication is a methodological review/analysis of eligibility criteria across multiple phase 3 RCTs, not an original report of a single trial's results with a time-to-event primary/key secondary endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intraoperative radiotherapy for resectable brain metastases: a systematic review and meta-analysis. PMID 40930278 · Radiother Oncol · 2025-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087). PMID 40930276 · Radiother Oncol · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. PMID 40929627 · J Clin Oncol · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4. PMID 40926359 · Diabetes Obes Metab · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC. PMID 40922529 · Cancer Sci · 2025-Nov 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial. PMID 40921806 · Nat Med · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus. PMID 40920289 · Adv Ther · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials. PMID 40915326 · Respir Med · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial. PMID 40915298 · Lancet Rheumatol · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease. PMID 40913446 · Mov Disord · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial. PMID 40913168 · Nat Med · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. PMID 40913104 · Leukemia · 2025-Nov 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 3 Panel · risk unclear |
| Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial. PMID 40908356 · Nat Med · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Adjuvant Capecitabine in Locoregionally Advanced Nasopharyngeal Carcinoma: A Meta-Analysis of Phase III Randomized Trials With Subgroup Analysis by Neoadjuvant Chemotherapy. PMID 40904055 · Head Neck · 2025-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. PMID 40900410 · Am J Clin Dermatol · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial. PMID 40899645 · Cancer Commun (Lond) · 2025-Nov 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 4 Figure · 24 Panel · risk unclear |
| Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study. PMID 40898993 · Phytother Res · 2025-Nov The record does not provide explicit evidence that the trial is Phase III/IIIb or Phase II/III. While it is a randomized, oncology trial with drug intervention and time-to-event endpoints, the phase is not specified and cannot be assumed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| "Tamoxifen for residual NF-PitNETs: A Proof-of-Concept study integrating receptor profiling, pilot trial, and target pathway analysis". PMID 40889098 · Endocrine · 2025-Nov The record describes a pilot randomized trial with a drug intervention and original results, but it is not a Phase III/IIIb or Phase II/III definitive trial, and its primary efficacy endpoint is radiographic tumor volume change at a fixed timepoint, not a time-to-event endpoint requiring Kaplan-Meier analysis or hazard ratio reporting. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies. PMID 40886218 · Am J Clin Dermatol · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial. PMID 40879891 · Ophthalmol Ther · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Sarecycline in Chinese Patients with Moderate-to-Severe Acne Vulgaris: Randomized Phase 3 Clinical Trial with Open-Label Follow-Up. PMID 40877730 · Dermatol Ther (Heidelb) · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials. PMID 40877636 · Br J Cancer · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial. PMID 40874954 · Paediatr Drugs · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled Trial of Resection Versus Thermal Ablation of Colorectal Cancer Liver Metastases (New Comet): Study Protocol. PMID 40858956 · Ann Surg Oncol · 2025-Nov 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis. PMID 40856088 · Ann Clin Transl Neurol · 2025-Nov 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. PMID 40854410 · Ann Oncol · 2025-Nov The record describes a secondary, long-term, biomarker-focused analysis of the ECOG-ACRIN 3805 (CHAARTED) trial. While it presents OS results from a randomized, oncology trial with drug intervention, it is not the original primary report of the Phase III trial results but a secondary analysis exploring prognostic factors. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. PMID 40850955 · Hypertens Res · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial. PMID 40849898 · Clin Pharmacol Ther · 2025-Nov 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study). PMID 40842343 · Diabetes Obes Metab · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ipsilateral High Thoracic Ultrasound-Guided Erector Spinae Plane Block for Post-Thoracotomy Shoulder Pain in Thoracic Cancer Surgeries: A Randomized Controlled Clinical Trial. PMID 40841229 · J Cardiothorac Vasc Anesth · 2025-Nov The record describes a randomized controlled trial in thoracic cancer patients, but it lacks explicit Phase III classification, involves a non-drug intervention (nerve block), and does not include a time-to-event oncology efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long-Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons. PMID 40830818 · Ann Clin Transl Neurol · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Including comparative observational evidence in trial-level surrogate endpoint evaluation: assessing relapse-free survival as a surrogate endpoint for overall survival in patients with acute myeloid leukemia post-transplant. PMID 40825512 · J Clin Epidemiol · 2025-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer. PMID 40817986 · Breast Cancer Res Treat · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. PMID 40816927 · Eur Urol · 2025-Nov 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| The pharmacokinetics and safety comparison of Zamerovimab and Mazorelvimab monoclonal antibodies vs. HRIG in category III rabies post-exposure prophylaxis: a stratified analysis by wound characteristics. PMID 40812204 · Biologicals · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial. PMID 40802027 · CNS Drugs · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Bayesian interim analysis and efficiency of phase III randomized trials. PMID 40789942 · Br J Cancer · 2025-Nov The record describes a methodological study analyzing efficiency of Bayesian interim analyses across many existing phase III oncology trials. It is not a report of a specific drug-containing randomized trial's efficacy results. No drug intervention is identified. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study. PMID 40782846 · J Allergy Clin Immunol Pract · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer. PMID 40781051 · Urol Oncol · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): 3-year follow-up of a randomised, controlled trial. PMID 40780241 · Lancet Rheumatol · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials. PMID 40779895 · Cancer Treat Rev · 2025-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Evaluating Benefits of Peristomal Mesh Placement at the Time of Radical Cystectomy and Ileal Conduit Formation: A Phase 3, Randomized Controlled Trial. PMID 40779615 · J Urol · 2025-Nov The trial is a randomized Phase III trial in oncology (bladder cancer), but it evaluates a surgical intervention (parastomal mesh placement) without a drug-containing arm. The primary endpoint is radiographic parastomal hernia rate, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Letter to the Editor: Intraoperative corticosteroid administration for resectable gastric cancer: a multicenter, randomized, open‑label, phase II/III study. PMID 40768025 · Gastric Cancer · 2025-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Ultrasound-Guided Stellate Ganglion Block Regulates Inflammatory Cytokines and Improves Short-Term Outcome after Cardiac Surgery with Cardiopulmonary Bypass: A Randomized Clinical Trial. PMID 40764224 · J Cardiothorac Vasc Anesth · 2025-Nov The study is a randomized trial in cardiac surgery, not oncology. It evaluates an intervention (stellate ganglion block) for inflammatory cytokines and short-term outcomes after cardiac surgery. It lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) and does not meet the oncology or efficacy endpoint criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trial. PMID 40759832 · Breast Cancer Res Treat · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic ovarian drilling vs. step-up gonadotropin therapy in infertile anovulatory polycystic ovary syndrome women resistant to sequential letrozole and gonadotropin-based ovulation induction cycles: a randomized controlled trial. PMID 40759374 · F S Sci · 2025-Nov 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy. PMID 40750720 · Am J Cardiovasc Drugs · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |